Pharma, device groups ask for more leeway to address misinformation
Regulatory NewsFerdous Al-Faruque
Biologics/ biosimilars/ vaccinesGuidanceMedical DevicesPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)